A common question in BCS III development - how do we ensure Q2 similarity when innovator composition is unknown?
The Reality:
- Q1 can be established from public sources
- Q2 cannot be directly verified
Yet regulators expect quantitative similarity, this is not about exact matching — it is about controlling risk.
What Q2 Similarity Really Means?
- Not matching exact excipient percentages
- But demonstrating no impact on drug absorption
How It Is Practically Demonstrated
1. Controlled Formulation Design
- Tight internal ranges
- Conservative excipient levels
- Avoid unnecessary functional excipients
2. Functional Equivalence
- Dissolution: ≥85% in 15 minutes (pH 1.2, 4.5, 6.8)
- Disintegration: comparable or faster than RLD
- Mechanical properties: hardness and friability aligned
3. Excipient Risk Management
- Critical excipients (SLS, PEG, surfactants): minimize and tightly control
- Non-critical excipients (MCC, lactose, starch): relatively flexible
4. Scientific Justification
- Define role of each excipient
- Justify selected quantities
- Demonstrate no impact on permeability
- Focus is on absorption consistency, not composition matching
Strategic Advantage
- Early engagement with regulators can significantly reduce risk
- Scientific advice (MHRA, EMA)
- Controlled correspondence (USFDA)
- Ask clearly: Is the proposed formulation acceptable for a BCS Class III biowaiver?
Common Mistake
Attempting to reverse-engineer innovator composition. This is not required and often misleading.
Final Takeaway
- Q2 similarity is not a number
- It is a scientific argument
Success depends on:
- Conservative formulation
- Functional equivalence
- Risk-based justification
Regulatory alignment
- In BCS Class III development, success lies in predictable performance, not precise copying.
Related:
- BCS Classification of Drugs and Its Significance
- Fundamentals of Biopharmaceutics and Pharmacokinetics
Resource Person: Moinuddin Syed Ph.D , MBA, PMP®
